The UK-headquartered biotech’s peptide-toxin conjugate showed a prolonged duration of response in advanced urothelial cancer patients in an early-stage trial compared with current standard of care, raising hopes for a differentiated profile.
Bicycle Therapeutics, plc’s updated Phase I/II data of BT8009 in urothelial cancer have shown potential for improved drug durability and tolerability when compared to Seagen Inc. /Astellas Pharma, Inc.’s standard-of-care Padcev, rousing optimism for the firm’s unique approach.
BT8009 is a bicyclic peptide-toxin conjugate candidate that targets Nectin-4, a cell adhesion molecule that is overexpressed in tumor cells...
Create an account to read this article
Already a subscriber?
The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.
Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.
Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.
